Saturday 17 October 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
98.06
4.67
−4.55%
Follow BLLN
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 1,320.00 |
P/S ratio |
4.59 | 4.59 | 4.26 |
Altman Z-Score |
— | — | 6.04 |
Altman Z″-Score (non-manufacturers) |
— | (0.24) | 7.37 |
P/FCF ratio |
0.00 | 0.00 | 82.68 |
Beneish M-Score |
— | — | (2.03) |
P/Operating CF |
113.67 | 113.67 | 120.39 |
P/B ratio |
0.00 | 0.00 | 2.71 |
Price to Tangible BV |
0.00 | 0.00 | 2.71 |
EV/Sales |
4.03 | 4.03 | 2.82 |
EV/EBITDA |
497.25 | 497.25 | 30.82 |
EV/Operating CF |
185.22 | 185.22 | 35.00 |
EV/FCF |
(246.78) | (246.78) | 54.78 |
Quick Ratio |
— | 7.62 | 11.21 |
Current Ratio |
— | 8.03 | 11.69 |
Net Debt/EBITDA |
0.00 | 3.96 | (15.70) |
Debt/Assets |
0.00% | 17.33% | 9.10% |
Debt/Equity |
0.00 | (0.21) | 0.12 |
Asset Turnover |
0.00 | 1.01 | 0.65 |
Operating CF/Net income |
0.65 | 1.00 | 8.43 |
Capex/Depreciation |
(0.88) | (0.45) | (0.75) |
Interest Coverage |
(21.24) | (19.76) | 168.66 |
| 0.00% | 0.00% | 2.56% | |
| 0.00% | (27.52%) | 0.62% | |
ROIC |
0.00% | 0.00% | 24.01% |
Return on Tangible Assets |
0.00% | (19.20%) | 0.55% |
Average Days of Receivables |
0.00 | 59.11 | 49.79 |
Research and Development Expense of Revenue |
31.25% | 23.98% | 16.19% |
Selling, General and Administrative Expense of Revenue |
89.77% | 59.94% | 46.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.77% | 5.48% | 5.22% |
Graham Net Nets |
(0.28) | (0.28) | 0.31 |
Graham Number |
0.00 | 0.00 | 6.50 |
Earnings Yield |
(1.60%) | (1.60%) | 0.08% |
Free Cash Flow Yield |
(0.36%) | (0.36%) | 1.21% |
Revenue per Share |
7.33 | 15.14 | 19.22 |
Operating CF per Share |
(5.49) | (4.10) | 1.55 |
Capex per Share |
(0.63) | (0.54) | (0.56) |
Free Cash Flow per Share |
(6.12) | (4.64) | 0.99 |
Cash per Share |
0.00 | 19.00 | 31.24 |
Shareholders Equity per Share |
0.00 | (24.97) | 30.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (24.97) | 30.24 |
Free Cash Flow |
(59.85) | (46.78) | 15.71 |
Working Capital |
— | 199.43 | 512.60 |
Capital Expenditures |
(6.17) | (5.40) | (8.88) |
Net Current Asset Value |
0.00 | (325.90) | 408.01 |
EV/EBIT |
0.00 | 0.00 | 53.72 |
Capex to Sales |
0.09 | 0.04 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 81.08 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 0.70 | 0.58 |
Cash ROIC |
0.00% | 597.87% | 1.52% |
Accounts Receivable Turnover |
0.00 | 0.00 | 9.20 |
Accounts Payable Turnover |
0.00 | 0.00 | 16.83 |
Inventory Turnover |
0.00 | 0.00 | 7.36 |
Average Days of Payables |
0.00 | 21.92 | 27.13 |
Days of Inventory on Hand |
0.00 | 44.48 | 66.26 |
Average Receivables |
— | — | 33.16 |
Average Payables |
— | — | 5.74 |
Average Inventory |
— | — | 13.14 |
Average Assets |
— | 151.03 | 467.36 |
Average Common Equity |
— | — | 114.22 |
Columns are period end dates